Esmolol

DEA Class;  Rx

Common Brand Names; Brevibloc

  • Antidysrhythmics, II; 
  • Beta-Blockers, Beta-1 Selective

Intravenous beta-blocker
Used for short-term treatment of supraventricular tachycardia, including atrial fibrillation and atrial flutter, noncompensatory sinus tachycardia, and perioperative tachycardia and hypertension
Rapid onset, short duration

Indicated for the short-term treatment of noncompensatory sinus tachycardia or paroxysmal supraventricular tachycardia (PSVT), including atrial fibrillation and atrial flutter.

For the short-term treatment of perioperative hypertension and/or tachycardia.
For the short-term treatment of postoperative hypertension and/or tachycardia.
For the treatment of ventricular tachycardia.
For the treatment of hypertensive urgency or hypertensive emergency.
For the treatment of thyrotoxicosis.

Hypersensitivity

Sinus bradycardia, 2°/3° heart block, cardiogenic shock, overt cardiac failure

Asthma/COPD

Sick sinus syndrome without permanent pacemaker

  • Hypotension, asymptomatic (25-38%)
  • Hypotension, symptomatic (12%)
  • Injection site pain (8%)
  • Nausea (7%)
  • Dizziness (3%)
  • Somnolence (3%)
  • Agitation (2%)
  • Confusion(2%)
  • Headache (2%)
  • Fatigue (1%)
  • Vomiting (1%)
  • Bradycardia
  • Chest pain
  • Anxiety
  • Anorexia
  • Depression
  • Abdominal discomfort
  • Constipation
  • Dry mouth
  • Dyspepsia
  • Taste perversion
  • Bronchospasm
  • Dyspnea
  • Nasal congestion
  • Wheezing

Anesthesia/surgery (myocardial depression), bronchospastic disease, cerebrovascular insufficiency, CHF, DM, hyperthyroidism/thyrotoxicosis, liver disease, renal impairment, peripheral vascular disease, myasthenic conditions

Sudden discontinuation can exacerbate angina and lead to myocardial infarction

Increased risk of stroke after surgery

Use in pheochromocytoma

Avoid abrupt withdrawal

Pregnancy Category: C; D in 2nd and 3rd trimesters (expert analysis)

Lactation: excretion in milk unknown; use with caution

Adults

500 mcg/kg/dose IV load and 300 mcg/kg/minute continuous IV infusion.

Geriatric

500 mcg/kg/dose IV load and 300 mcg/kg/minute continuous IV infusion.

Adolescents

Safety and efficacy have not been established; however, 1,000 mcg/kg/dose IV load and 1,000 mcg/kg/minute continuous IV infusion have been used.

Children

Safety and efficacy have not been established; however, 1,000 mcg/kg/dose IV load and 1,000 mcg/kg/minute continuous IV infusion have been used.

Infants

Safety and efficacy have not been established; however, 1,000 mcg/kg/dose IV load and 1,000 mcg/kg/minute continuous IV infusion have been used.

Neonates

Safety and efficacy have not been established; however, 500 mcg/kg/dose IV load and 1,000 mcg/kg/minute continuous IV infusion have been used.

Esmolol hydrochloride

infusion bags

  • 2g/100mL
  • 2.5g/250mL

injectable solution

  • 10mg/mL
  • 20mg/mL

About the Author

You may also like these

0